Branford, United States
IsoPlexis, founded in 2013, is a pioneering company in the fields of Biotechnology, Health Care, Health and Wellness, and Medical Devices. Headquartered in the United States, IsoPlexis is at the forefront of transforming immune medicine with their innovative, high-resolution systems designed to enhance the development and personalization of curative medicines. Their mission is encapsulated in their slogan: "Powerful Biology Accelerating the Future of Medicine."
The company has recently demonstrated its growth potential through a significant $85.00M Series D investment, secured on 07 January 2021. This latest funding round was backed by prominent investors including BlackRock, Ally Bridge Group, and Perceptive Advisors. This strong backing from leading investment groups underscores IsoPlexis's promising role in spearheading advancements in immune medicine, which appeals greatly to venture capitalists seeking impactful and innovative companies in the health tech sector.
Eccogene